84 related articles for article (PubMed ID: 27599425)
41. Generation of activated and antigen-specific T cells with cytotoxic activity after co-culture with dendritic cells.
Märten A; Greten T; Ziske C; Renoth S; Schöttker B; Buttgereit P; Schakowski F; von Rücker A; Sauerbruch T; Schmidt-Wolf IH
Cancer Immunol Immunother; 2002 Mar; 51(1):25-32. PubMed ID: 11845257
[TBL] [Abstract][Full Text] [Related]
42. [Tumor specific antigen and cytotoxic T lymphocytes].
Uenaka A; Nakayama E
Nihon Rinsho; 2005 Apr; 63 Suppl 4():568-73. PubMed ID: 15861712
[No Abstract] [Full Text] [Related]
43. Expansion of CD8+ cytotoxic T cells in vitro and in vivo using MHC class I tetramers.
Savage P; Millrain M; Dimakou S; Stebbing J; Dyson J
Tumour Biol; 2007; 28(2):70-6. PubMed ID: 17264539
[TBL] [Abstract][Full Text] [Related]
44. Evidence for cytotoxic T lymphocyte response against human lung cancer: reconstitution of antigenic epitope with peptide eluted from lung adenocarcinoma MHC class I.
Calhoun RF; Naziruddin B; Enriquez-Rincon F; Duffy BF; Ritter JM; Sundaresan S; Patterson GA; Cooper JD; Mohanakumar T
Surgery; 2000 Jul; 128(1):76-85. PubMed ID: 10876189
[TBL] [Abstract][Full Text] [Related]
45. Clonal diversity of cytotoxic T lymphocytes that recognize autologous oral squamous cell carcinoma.
Kobayashi J; Hirohashi Y; Torigoe T; Michifuri Y; Yamamoto T; Tamura Y; Kamiguchi K; Miyazaki A; Yamaguchi A; Hariu H; Hiratsuka H; Sato N
Hum Immunol; 2009 Feb; 70(2):89-95. PubMed ID: 19124056
[TBL] [Abstract][Full Text] [Related]
46. Selective responsiveness to common gamma chain cytokines in peripheral blood-derived cytotoxic T lymphocytes induced by Melan-A/MART-1(27-35)targeted active specific immunotherapy.
von Holzen U; Adamina M; Bolli M; Weber WP; Zajac P; Groeper C; Reschner A; Feder C; Schumacher R; Marti W; Oertli D; Heberer M; Spagnoli GC
Int J Cancer; 2005 Jun; 115(2):248-55. PubMed ID: 15688403
[TBL] [Abstract][Full Text] [Related]
47. Chemotherapeutic drugs may be used to enhance the killing efficacy of human tumor antigen peptide-specific CTLs.
Correale P; Del Vecchio MT; La Placa M; Montagnani F; Di Genova G; Savellini GG; Terrosi C; Mannucci S; Giorgi G; Francini G; Cusi MG
J Immunother; 2008; 31(2):132-47. PubMed ID: 18481383
[TBL] [Abstract][Full Text] [Related]
48. Induction of melanoma antigen-specific cytotoxic T lymphocytes in vitro by stimulation with B7-expressing human melanoma cell lines.
Fenton RG; Turcovski-Corrales SM; Taub DD
J Immunother; 1998 Mar; 21(2):95-108. PubMed ID: 9551360
[TBL] [Abstract][Full Text] [Related]
49. Cyclin-dependent kinaselike 5 is a novel target of immunotherapy in adult T-cell leukemia.
Kawahara M; Hori T; Matsubara Y; Okawa K; Uchiyama T
J Immunother; 2007; 30(5):499-505. PubMed ID: 17589290
[TBL] [Abstract][Full Text] [Related]
50. Allogeneic T lymphocytes as a source of peptide-dependent T cells specific for myeloma cells.
Geffroy-Luseau A; Moreau-Aubry A; Bataille R; Pellat-Deceunynck C
Int Immunol; 2005 Sep; 17(9):1193-200. PubMed ID: 16027137
[TBL] [Abstract][Full Text] [Related]
51. In vitro generation of tumor specific T cells that recognize a shared antigen of AML: molecular characterization of TCR genes.
Coppage M; Belanger T; Zauderer M; Sahasrabudhe D
Leuk Res; 2007 Feb; 31(2):195-202. PubMed ID: 16750565
[TBL] [Abstract][Full Text] [Related]
52. Regeneration of Tumor-Antigen-Specific Cytotoxic T Lymphocytes from iPSCs Transduced with Exogenous TCR Genes.
Maeda T; Nagano S; Kashima S; Terada K; Agata Y; Ichise H; Ohtaka M; Nakanishi M; Fujiki F; Sugiyama H; Kitawaki T; Kadowaki N; Takaori-Kondo A; Masuda K; Kawamoto H
Mol Ther Methods Clin Dev; 2020 Dec; 19():250-260. PubMed ID: 33102617
[TBL] [Abstract][Full Text] [Related]
53. Hematopoietic lineage-converted T cells carrying tumor-associated antigen-recognizing TCRs effectively kill tumor cells.
Hu F; Huang D; Luo Y; Zhou P; Lv C; Wang K; Weng Q; Liu X; Guan Y; Geng Y; Du J; Chen J; Wang J; Wu H
J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32669292
[TBL] [Abstract][Full Text] [Related]
54. [Application of iPS Cell-Derived NKT Cells to Cancer Immunotherapy].
Motohashi S; Iinuma T; Kurokawa T; Koseki H
Gan To Kagaku Ryoho; 2020 Oct; 47(10):1411-1414. PubMed ID: 33130731
[TBL] [Abstract][Full Text] [Related]
55. Transplantation of iPS-Derived Tumor Cells with a Homozygous MHC Haplotype Induces GRP94 Antibody Production in MHC-Matched Macaques.
Ishigaki H; Maeda T; Inoue H; Akagi T; Sasamura T; Ishida H; Inubushi T; Okahara J; Shiina T; Nakayama M; Itoh Y; Ogasawara K
Cancer Res; 2017 Nov; 77(21):6001-6010. PubMed ID: 28882998
[TBL] [Abstract][Full Text] [Related]
56. Two Weeks' Notice from Allogeneic Sources.
Anczurowski M; Hirano N
Clin Cancer Res; 2018 Nov; 24(21):5195-5197. PubMed ID: 29941482
[TBL] [Abstract][Full Text] [Related]
57. [Development of "Off the Shelf" T Cells for Cancer Immunotherapy].
Nagano S; Kawamoto H
Gan To Kagaku Ryoho; 2023 May; 50(5):561-566. PubMed ID: 37218312
[TBL] [Abstract][Full Text] [Related]
58. Regeneration of CD8αβ T Cells from T-cell-Derived iPSC Imparts Potent Tumor Antigen-Specific Cytotoxicity.
Maeda T; Nagano S; Ichise H; Kataoka K; Yamada D; Ogawa S; Koseki H; Kitawaki T; Kadowaki N; Takaori-Kondo A; Masuda K; Kawamoto H
Cancer Res; 2016 Dec; 76(23):6839-6850. PubMed ID: 27872100
[TBL] [Abstract][Full Text] [Related]
59. Cloning and expansion of antigen-specific T cells using iPS cell technology: development of "off-the-shelf" T cells for the use in allogeneic transfusion settings.
Kawamoto H; Masuda K; Nagano S; Maeda T
Int J Hematol; 2018 Mar; 107(3):271-277. PubMed ID: 29388165
[TBL] [Abstract][Full Text] [Related]
60. Development and characterization of naive single-type tumor antigen-specific CD8
Lei F; Haque M; Sandhu P; Ravi S; Song J; Ni B; Zheng S; Fang D; Jia H; Yang JM; Song J
Oncoimmunology; 2017; 6(7):e1334027. PubMed ID: 28811978
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
